Anders Rabbe is appointed acting CEO of WntResearch and will take position on October 15, replacing Peter Morsing. The NeoFox study is currently in a key phase, when the recruitment of patients must intensify to enable the analysis of data. Peter Morsing will remain in an advisory role during his period of notice, until January 2021. Over the course of about ten years, until November 2019, Anders was the CEO of Isofol Medical AB (publ). He further prepared the company for the commercialization and out-licensing of its drug candidate. Anders has extensive experience of managing business development, clinical projects and regulatory processes. As the CEO of listed companies on Nasdaq First North Premier, Anders also is well experienced with the requirements and obligations of a listed company.